Michael Wonder Michael Wonder
Founder / CEO

About MAESTrO

MAESTrO is an online market access data resource and consultancy based in Sydney, Australia.

Building on Michael’s 20 years’ experience in health technology assessment, we constantly invest in expert research, analysis, customer support and design to create a comprehensive database of global market access submissions and outcomes.

Thomas Mulvaney
Thomas Mulvaney
Development
Thomas Crowley
Thomas Crowley
Development manager
Mark Reuten
Mark Reuten
User Experience

Our people

MAESTrO’s growing team reflects the growing demand for our unique services. As a privately-owned, founder-led company MAESTrO is agile and responsive, meeting your specific needs without getting in your way. We invest in research, customer support and great design.

Thomas Mulvaney
Justine Biggs
Data magician
Rob Gower
Rob Gower
Marketing manager

About Michael

Michael gained his B.Sc (Hons) in Biochemistry & Pathology from the University of Melbourne and a B. Pharm. from the Victorian College of Pharmacy, before working as a hospital pharmacist for five years. He then moved to Novartis Pharmaceuticals Australia as their first Health Economics Manager, working on strategic development and preparation of reimbursement and/or pricing submissions, before being appointed Director of Global Pricing and Market Access Operations for Novartis Pharma AG.

Since 2011, Michael has been an independent consultant on biopharmaceutical reimbursement and pricing matters. He has also acted as an expert advisor to the Masters of Science in International Health Technology Assessment, Pricing and Reimbursement at the University of Sheffield and the Distance Learning Certificate Program in Health Economics and Outcomes Research at the University of Washington.

Michael has a strong record of speaking and publishing on medical and health economy topics, including:

What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry?
Wonder M, 2014. Expert Review of Pharmacoeconomics & Outcomes Research, volume: 12, Issue: 6, page/s: 1-3
Is there any evidence that the Trans Pacific Partnership Agreement will threaten access to affordable medicines and health equity in New Zealand?
Wonder M, Milne R, 2014. Health Policy, volume: 116, issue: 2-3, page/s: 234-5
Early scientific advice obtained simultaneously from regulators and payers: findings from a pilot study in Australia
Wonder M, Backhouse M, Hornby E., 2013. Value in Health, volume: 16, issue: 6, page/s: 1067-73
Assessment of the therapeutic value of new medicines marketed in Australia.
Wonder MJ, 2013. Journal of Pharmaceutical Policy and Practice, volume: 6, issue:, page/s: 7
Delays in access to affordable medicines: putting policy into perspective
Wonder M, Chin C, 2013. Australian Health Review, volume: 37, issue: 4, page/s: 430
Comparing subsidized access to medicines across payer systems
Wonder M, Milne R, 2013. Pharmacoeconomics, volume: 31, issue: 2, page/s: 173-4
Australian managed entry scheme; a new manageable process for the reimbursement of new medicines?
Wonder M, Backhouse ME, Sullivan SD, 2012. Value in Health, volume: 15, issue: 3, page/s: 586-90
Patient access to new cancer drugs in the United States and Australia
Wonder M, Backhouse ME, Sullivan SD, 2012. Value in Health, volume: 15, issue: 2, page/s: 397-9
Response to PHARMAC on access to new medicines in New Zealand compared to Australia
Milne R, Wonder M. New Zealand Medical Journal, volume: 124, issue: 1347, page/s: 91-3
Access to new medicines in New Zealand compared to Australia
Wonder M, Milne R. New Zealand Medical Journal, volume: 124, issue: 1346, page/s: 12-28
Early dialogue between the developers of new technologies and pricing and reimbursement agencies. A pilot study
Backhouse M, Wonder M, Hornby E, Kilburg A, Mayer FK, 2001. Value in Health, volume: 14, issue: 4, page/s: 608-15
Are Australians able to access new medicines on the Pharmaceutical Benefits Scheme in a more or less timely manner? An analysis of Pharmaceutical Benefits Advisory Committee recommendations 1999-2003
Wonder M, Neville M, Parsons R, 2006. Value in Health, volume: 9, issue: 4, page/s: 205-12